MiNK Therapeutics (NASDAQ:INKT – Get Rating) will issue its quarterly earnings data before the market opens on Thursday, May 11th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link. MiNK Therapeutics Stock Performance […]
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) Director Garo H. Armen acquired 100,000 shares of the business’s stock in a transaction on Tuesday, May 2nd. The stock was acquired at an average cost of $0.95 per share, for a total transaction of $95,000.00. Following the transaction, the director now owns 1,978,010 shares of the company’s […]
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) Director Garo H. Armen purchased 100,000 shares of the stock in a transaction that occurred on Tuesday, May 2nd. The stock was acquired at an average cost of $0.95 per share, with a total value of $95,000.00. Following the acquisition, the director now owns 1,978,010 shares in the […]
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 48,700 shares, a growth of 34.2% from the March 31st total of 36,300 shares. Based on an average daily volume of 17,100 shares, the short-interest ratio is […]
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) – Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for MiNK Therapeutics in a report issued on Wednesday, April 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.71) per share for the year, up from their […]